Answers are grounded in this paper and cite their sources.
Plasma inflammatory protein biomarkers associated with clinical milestone heterogeneity in Parkinson's disease (PD) remain undefined. We measured 92 inflammation-related plasma proteins in 82 PD patients using the Olink Proximity Extension Assay. No proteins differed significantly between fallers and non-fallers. However, among fallers, plasma interleukin-24 showed the strongest correlation with observed time to first fall (unadjusted r = 0.752, q = 0.071), and this signal was also observed in an exploratory covariate-adjusted model (q = 0.030). Colony-stimulating factor 1 showed a comparable but non-significant correlation. In group comparisons for symptomatic orthostatic hypotension, CCL11 differed significantly between patients with and without symptomatic orthostatic hypotension (q = 0.0004). These exploratory findings highlight candidate inflammatory protein profiles related to milestone heterogeneity in PD, warranting validation in longitudinal cohorts.
No takes yet. Share an insight, caveat, or question.
Iwaoka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: